Long-term study of KRP-108

Phase III long-term study of KRP-108 -open-label, non-controlled, long-term study of KRP-108 in pediatric bronchial asthma-

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223577

Enrollment

Registered

2017-06-28

Start date

2017-07-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

investigational material(s) Generic name etc : KRP-108 INN of investigational material : Fluticasone/Formoterol Therapeutic category code : 229 Other agents affecting respiratory organs Dosage and Adm

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Known history of bronchial asthma for > 12 weeks.

Exclusion criteria

Exclusion criteria: Complication of chronic pulmonary disease without bronchial asthma and diseases affecting respiratory function. Complication of hypokalemia.

Design outcomes

Primary

Measure	Time frame
safety Adverse events, and others Vital signs, etc	—

Secondary

Measure	Time frame
efficacy Morning PEF value, etc The change from baseline	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026